The Lustgarten Foundation is the largest private funder of the world’s preeminent pancreatic cancer researchers.
To date, we have funded more than $250 million in research grants and been a leading force in every major advancement in pancreatic cancer research.
Progress is paramount. We drive bold, innovative research with the singular mission: transforming pancreatic cancer into a curable disease.
(WOODBURY, N.Y.) – The Lustgarten Foundation and the American Association for Cancer Research (AACR) announced three grants for the coming year. The Lustgarten Foundation-Swim Across America-AACR Pancreatic Cancer Early Detection Research Grant represents a joint effort to support innovative research to advance efforts toward the early detection and interception of pancreatic cancer. The proposed project […]
Solving the unique complexities of pancreatic cancer requires complex thinking and diversity of thought, education,training, background and experience. We are committed to prioritizing and promoting diversity and inclusion acrossthe organization, including staff, volunteer leadership and research portfolio. ResearchA rich field of experience and perspectives working on the complex problems associated with pancreatic cancer increases the […]
WOODBURY, N.Y., Sept 16, 2022 /PRNewswire/ — The Lustgarten Foundation announced today that the Lustgarten Equity, Accessibility, and Diversity (LEAD) Project’s inaugural grant will be awarded to Jen Jen Yeh, MD, Professor & Vice Chair of Research, Surgery, Division of Oncology Professor, Pharmacology Member, Lineberger Comprehensive Cancer Center for her PROmoting CLinicAl TrIal EngageMent for […]
News From Lustgarten
Researchers at The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center have found that a new synthetic lethal agent could be an effective treatment for pancreatic cancers with DNA damage repair (DDR) defects.
An extremely common response to cellular stress may be the key to pancreatic cancer in people with obesity, pointing to a new direction for therapy of this difficult-to-treat cancer.
The FDA has granted an orphan drug designation to the novel PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of patients with pancreatic cancer.1
From Nurse to Patient
When Susan was diagnosed with pancreatic cancer, cutting-edge drugs and a supportive medical team helped her go from patient to survivor. Now she raises funds for continued research through a Lustgarten Foundation Walk for Research.Read Susan’s Story